Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,951.60
(
0.00%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
103.17
(
2.48%
)
Bitcoin
68,458.00
(
-0.48%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: read_this_n0w post# 126967

Thursday, 09/29/2011 4:10:12 PM

Thursday, September 29, 2011 4:10:12 PM

Post# of 257295
Bloomberg piece says HGSI having the same kinds of reimbursement issues as DNDN:

http://www.bloomberg.com/news/2011-09-29/biotech-investors-bow-out-after-approvals-as-sales-hurdles-grow.html

Maybe the problem with Benlysta (as with Provenge) is that the demand is simply less than what some investors thought.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today